Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

New model predicts HCC risk in noncirrhotic chronic hepatitis B patients, improving early detection strategies.

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

In these cases, the major issue is to distinguish FNH-like nodules from hepatocellular carcinoma (HCC). A mesenchymal hamartoma is another uncommon benign lesion, which is composed of bile ducts ...

Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.

Oncolytic viruses (OVs) are viruses that infect and kill cancer cells while sparing healthy tissue, making them a promising therapeutic option in cancer ...